U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SAN DIEGO, Jan. 27, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and archived for replay through Tuesday, May 10, 2016.
About Retrophin
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam®, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), nephrotic syndrome and others. For additional information, please visit www.retrophin.com.
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
